Retatrutide adds GIP receptor activation that survodutide lacks, making it a triple agonist (GIP + GLP-1 + glucagon) versus survodutides dual agonism (GLP-1 + glucagon)
After 4 weeks at therapeutic doses, most users report 50-70% reduction in pain, significantly improved function, and ability to resume modified training or activities
And thank you, Louise Cunningham, for facilitating the interview
This article will discuss: What GLP-1s are
Due to the high expression profile of GLP-1R in pancreatic -cells, GLP-1 analogs (such as exendin-4) have been modified by different methods (to prolong half-life, maintain receptor binding affinity and reduce renal drug accumulation) for theranostic purposes and serve as excellent templates for future cardiovascular drug development[178-184]
Concurrently, redox homeostasis, mitochondrial biogenesis, and mitophagy intricately contribute to tumor dynamics, underscoring the multifaceted roles of mitochondria in CRC pathogenesis and progression